Free Trial

STERIS (STE) Stock Forecast & Price Target

STERIS logo
$243.07 +6.83 (+2.89%)
Closing price 08/8/2025 03:59 PM Eastern
Extended Trading
$242.84 -0.24 (-0.10%)
As of 08/8/2025 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STERIS - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
6

Based on 8 Wall Street analysts who have issued ratings for STERIS in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 2 have given a hold rating, and 6 have given a buy rating for STE.

Consensus Price Target

$270.33
11.22% Upside
According to the 8 analysts' twelve-month price targets for STERIS, the average price target is $270.33. The highest price target for STE is $288.00, while the lowest price target for STE is $250.00. The average price target represents a forecasted upside of 11.22% from the current price of $243.07.
Get the Latest News and Ratings for STE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for STERIS and its competitors.

Sign Up

STE Analyst Ratings Over Time

TypeCurrent Forecast
8/9/24 to 8/9/25
1 Month Ago
7/10/24 to 7/10/25
3 Months Ago
5/11/24 to 5/11/25
1 Year Ago
8/10/23 to 8/9/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
2 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$270.33$263.83$258.75$243.60
Forecasted Upside11.22% Upside14.49% Upside14.22% Upside3.23% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Moderate Buy

STE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

STE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

STERIS Stock vs. The Competition

TypeSTERISMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.81
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside11.22% Upside27,876.90% Upside13.84% Upside
News Sentiment Rating
Positive News

See Recent STE News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/22/2025KeyCorp
3 of 5 stars
Brett Fishbin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$277.00 ➝ $288.00+28.78%
7/15/2025Morgan Stanley
3 of 5 stars
Patrick Wood
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$260.00 ➝ $276.00+22.33%
5/29/2025Jefferies Financial Group
2 of 5 stars
David Windley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$263.00+7.33%
5/16/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform
5/16/2025JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Turkaly
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetMarket Outperform ➝ Market Outperform$265.00 ➝ $280.00+11.84%
5/15/2025Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Etoch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$250.00 ➝ $250.00+1.92%
4/7/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mike Matson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
2/3/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Bednar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$260.00 ➝ $265.00+21.26%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:44 AM ET.


Should I Buy STERIS Stock? STE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, August 7, 2025. Please send any questions or comments about these STERIS pros and cons to contact@marketbeat.com.

STERIS
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in STERIS plc:

  • The current stock price is around $234, which reflects a strong performance in the medical equipment sector.
  • STERIS plc recently reported quarterly earnings that exceeded expectations, with earnings per share of $2.34, indicating robust financial health and effective management.
  • The company has shown a revenue increase of 8.8% compared to the same quarter last year, suggesting strong growth potential.
  • STERIS plc has a solid dividend yield of approximately 1.1%, which can provide a steady income stream for investors.
  • Analysts have a positive outlook on the stock, with an average price target of around $270.33, indicating potential for price appreciation.

STERIS
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in STERIS plc for these reasons:

  • The stock has a relatively high PE ratio of 38.08, which may indicate that it is overvalued compared to its earnings.
  • Despite recent growth, the company's beta of 0.92 suggests that it is less volatile than the market, which may limit potential high returns.
  • STERIS plc's dividend payout ratio is around 36.77%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities.
  • Recent analyst ratings show mixed sentiments, with some analysts downgrading their ratings, which could indicate uncertainty in future performance.
  • The medical equipment industry can be subject to regulatory changes and market fluctuations, which may pose risks to STERIS plc's operations and profitability.

STE Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for STERIS is $270.33, with a high forecast of $288.00 and a low forecast of $250.00.

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STE shares.

According to analysts, STERIS's stock has a predicted upside of 11.22% based on their 12-month stock forecasts.

Over the previous 90 days, STERIS's stock had 1 upgrade by analysts.

STERIS has been rated by research analysts at Citigroup, Jefferies Financial Group, JMP Securities, KeyCorp, Morgan Stanley, and Stephens in the past 90 days.

Analysts like STERIS less than other "medical" companies. The consensus rating score for STERIS is 2.75 while the average consensus rating score for "medical" companies is 2.80. Learn more on how STE compares to other companies.


This page (NYSE:STE) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners